Figure 2. CPPTL eliminated AML cells in vivo and prolonged survival in a mouse model.

(A) Schematic of the xenotransplantation experiment. NOD/SCID mice received 2.5 Gy irradiation before transplantation of 1 × 10⁷ primary human AML MNCs via the tail vein. AML mice were randomly distributed to groups receiving 100 mg/kg of DMA-CPPTL via i.g. administration or vehicle every 48 h for 7 treatments. The positive control group received 2 mg/kg of ADR, a traditional chemotherapy drug, via i.v. injection every 72 h for 4 treatments. After 8 weeks, we detected CD45⁺ cells in peripheral blood to assess the success of AML engraftment. The survival curve shows only mice transplanted with AML successfully. (B) Synthesis of DMA-CPPTL. (C) Survival curves of 2.5 Gy-irradiated NOD/SCID mice transplanted with primary AML MNCs receiving treatment with DMA-CPPTL (n = 7, shown in blue), ADR (n = 9, shown in red) and vehicle control (n = 9, shown in black). (D) FACS analysis of the percentage of CD45⁺ cell engraftment in bone marrow after natural death of AML mice. (E) Percentage of mice exhibiting varying degrees of leukemic cell engraftment.